Company Overview - Dingdang Health (09886.HK) closed at HKD 0.99 per share, up 23.75% with a trading volume of 33.3 million shares and a turnover of HKD 32.05 million, showing a volatility of 27.5% [1] - Over the past month, Dingdang Health has seen a cumulative increase of 45.45%, and a year-to-date increase of 60%, outperforming the Hang Seng Index by 25.45% [2] Financial Performance - As of December 31, 2024, Dingdang Health reported total revenue of CNY 4.669 billion, a year-on-year decrease of 3.87% - The company recorded a net loss attributable to shareholders of CNY 376 million, a significant decline of 66.73% year-on-year - The gross profit margin stood at 32.95%, with a debt-to-asset ratio of 36.18% [2] Valuation and Industry Comparison - Currently, there are no institutional investment ratings for Dingdang Health - The average price-to-earnings (P/E) ratio for the pharmaceutical and biotechnology industry is -2.05x, with a median of 1.44x - Dingdang Health's P/E ratio is -2.6x, ranking 148th in the industry, compared to peers such as Jingxin Pharmaceutical (00858.HK) at 1.32x and Hengrui Medicine (00013.HK) at 6.01x [3] Industry Positioning - Dingdang Health is recognized as a pioneer in providing rapid digital healthcare services in China, focusing on an online-to-offline model for instant pharmaceutical retail and medical consultation - The company aims to innovate and reshape the healthcare industry in China through technological advancements and business model innovation, continuing to invest in innovation to create value for the pharmaceutical industry and society [3] Upcoming Events - The company is scheduled to disclose its interim report for the fiscal year 2025 on August 22, 2025 [4]
叮当健康（09886.HK）8月21日收盘上涨23.75%，成交3205.23万港元